留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

妇科肿瘤铂类药物临床应用指南

中华医学会妇科肿瘤学分会

中华医学会妇科肿瘤学分会. 妇科肿瘤铂类药物临床应用指南[J]. 协和医学杂志, 2021, 12(6): 881-901. doi: 10.12290/xhyxzz.2021-0690
引用本文: 中华医学会妇科肿瘤学分会. 妇科肿瘤铂类药物临床应用指南[J]. 协和医学杂志, 2021, 12(6): 881-901. doi: 10.12290/xhyxzz.2021-0690
Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 881-901. doi: 10.12290/xhyxzz.2021-0690
Citation: Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 881-901. doi: 10.12290/xhyxzz.2021-0690

妇科肿瘤铂类药物临床应用指南

doi: 10.12290/xhyxzz.2021-0690
详细信息

    通信作者:孔北华1,刘继红2,谢幸3,马丁4.
    1. 山东大学齐鲁医院妇产科,济南 250012,E-mail:kongbeihua@sdu.edu.cn
    2. 中山大学肿瘤防治中心妇科,广州 510060,E-mail:liujh@sysucc.org.cn
    3. 浙江大学医学院附属妇产科医院,杭州 310006,E-mail:xiex@zju.edu.cn
    4. 华中科技大学同济医学院附属同济医院妇产科,武汉 430030,E-mail:dma@tjh.tjmu.edu.cn

  • 中图分类号: R737.3; R730.53

Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors

More Information

    Corresponding authors: KONG Beihua1, LIU Jihong2, XIE Xing3, MA Ding4.
    1. Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China, E-mail: kongbeihua@sdu.edu.cn
    2. Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China, E-mail: liujh@sysucc.org.cn
    3. Women's Hopital, School of Medicine Zhejiang University, Hangzhou 310006, China, E-mail: xiex@zju.edu.cn
    4. Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China, E-mail: dma@tjh.tjmu.edu.cn

  • 摘要: 铂类药物是作用机制独特的广谱抗肿瘤药物,以铂类药物为基础的联合化疗是妇科肿瘤最常用的化疗方案。紫杉醇联合卡铂方案是上皮性卵巢癌的首选标准方案,顺铂是子宫颈癌的首选铂类药物。耐药是铂类药物临床应用中面临的最大挑战,此外,应积极预防和处理铂类药物不良反应及过敏反应。《妇科肿瘤铂类药物临床应用指南》旨在规范铂类药物的临床用药方案及用药后管理。
    利益冲突:共识制订工作组所有参与人员均声明不存在利益冲突
    执笔专家组
    孔北华,刘继红,向阳,张国楠,陈刚,尹如铁,李秀琴,姜洁,沈源明,刘红,蒋芳,邓婷,李小平,鹿欣,谢幸,马丁
    编审专家组(以姓氏笔画为序):
    万小平(上海市第一妇婴保健院),马丁(华中科技大学同济医学院附属同济医院),王丹波(辽宁省肿瘤医院),王世宣(华中科技大学同济医学院附属同济医院),王建六(北京大学人民医院),王新宇(浙江大学医学院附属妇产科医院),尹如铁(四川大学华西第二医院),孔北华(山东大学齐鲁医院),邓婷(中山大学肿瘤防治中心),曲芃芃(天津市中心妇产科医院),吕卫国(浙江大学医学院附属妇产科医院),向阳(中国医学科学院北京协和医院),刘红(四川省肿瘤医院/四川省第二人民医院),刘继红(中山大学肿瘤防治中心),李小平(北京大学人民医院),李秀琴(中国医科大学附属盛京医院),杨兴升(山东大学齐鲁医院),杨佳欣(中国医学科学院北京协和医院),吴小华(复旦大学附属肿瘤医院),吴令英(中国医学科学院肿瘤医院),汪辉(浙江大学医学院附属妇产科医院),沈铿(中国医学科学院北京协和医院),沈源明(浙江大学医学院附属妇产科医院),宋坤(山东大学齐鲁医院),张国楠(四川省肿瘤医院/四川省第二人民医院),陈刚(华中科技大学同济医学院附属同济医院),赵霞(四川大学华西第二医院),哈春芳(宁夏医科大学/宁夏医科大学总医院),姜洁(山东大学齐鲁医院),徐丛剑(复旦大学附属妇产科医院),高雨农(北京大学肿瘤医院),郭瑞霞(郑州大学第一附属医院),崔恒(北京大学人民医院),康山(河北医科大学第四医院),鹿欣(复旦大学附属妇产科医院),梁志清(陆军军医大学第一附属医院),蒋芳(中国医学科学院北京协和医院),程文俊(南京医科大学第一附属医院/江苏省人民医院),谢幸(浙江大学医学院附属妇产科医院)
  • 图  1  铂类药物引发的轻度、严重以及致命药物反应处理流程

    Ⅳ.静脉注射;IP.腹腔注射;IM.肌内注射

    表  1  推荐级别及其代表意义

    推荐级别 代表意义
    1类 基于高级别临床研究证据,专家意见高度一致
    2A类 基于低级别临床研究证据,专家意见高度一致;或基于高级别临床研究证据,专家意见基本一致
    2B类 基于低级别临床研究证据,专家意见基本一致
    3类 不论基于何种级别临床研究证据,专家意见明显分歧
    下载: 导出CSV

    表  2  三代铂类药物的药理特点和不良反应比较

    铂类 药物名称 理化性质 t1/2总铂 不良反应
    肾毒性 耳毒性 外周神经毒性 白细胞减少 血小板减少 消化道毒性 剂量限制性毒性
    第一代 顺铂 微溶 >5 d 很强 很强 稍强 很强 肾毒性
    第二代 卡铂 略溶 (5.8±1.6)d 很强 很强 骨髓抑制
    第二代 奈达铂 略溶 平均9 h 很强 骨髓抑制
    第三代 奥沙利铂 微溶 - 很强 稍强 外周神经毒性
    第三代 洛铂 略溶 (6.8±4.3)d 稍强 很强 稍强 血小板减少
    下载: 导出CSV

    表  3  子宫颈癌根治性同步放化疗的化疗方案

    方案 用法
    顺铂单药[2, 6-7] 顺铂30~40 mg/m2,静脉滴注>1 h,每周1次
    卡铂单药[8] 卡铂AUC=2,静脉滴注>1 h,每周1次
    AUC:曲线下面积
    下载: 导出CSV

    表  4  早期子宫颈癌术后辅助化疗方案

    药物 剂量 指征 疗程数
    紫杉醇 135~175 mg/m2 淋巴结转移和/或宫旁浸润 6个
    顺铂 75 mg/m2 (1)≥2/3深层间质浸润 ·任意1条,3个
    ·≥任意2条,6个
    (2)组织病理学分级为中低分化(G2~G3)
    (3)淋巴血管间隙受侵
    (4)肿瘤最大径>4 cm
    下载: 导出CSV

    表  5  ⅣB期和复发性子宫颈癌的挽救/姑息化疗方案

    方案 用法
    顺铂+紫杉醇+贝伐珠单抗[21] 紫杉醇135 mg/m2,静脉滴注>24 h,或紫杉醇175 mg/m2,静脉滴注>3 h;顺铂50 mg/m2;贝伐珠单抗15 mg/kg,静脉滴注30~90 min;每3周1次
    卡铂+紫杉醇+贝伐珠单抗[20-21] 紫杉醇175 mg/m2,静脉滴注>3 h;卡铂AUC=5,静脉滴注>1 h;贝伐珠单抗15 mg/kg,静脉滴注30~90 min;每3周1次
    顺铂+紫杉醇[17] 紫杉醇135 mg/m2,静脉滴注>24 h,第1天;顺铂50 mg/m2,静脉滴注>1 h,第2天;每3周1次
    卡铂+紫杉醇[20] 紫杉醇175 mg/m2,静脉滴注>3 h;卡铂AUC=5,静脉滴注>1 h;每3周1次
    顺铂+托泊替康[18] 托泊替康0.75 mg/m2,静脉滴注30 min,第1~3天;顺铂50 mg/m2,静脉滴注>1 h,第1天;每3周1次
    AUC:同表 3
    下载: 导出CSV

    表  6  子宫颈神经内分泌癌的化疗方案

    方案 用法
    顺铂+依托泊苷[32-33] ①顺铂25 mg/m2,静脉滴注,第1~3天;依托泊苷100 mg/m2,静脉滴注,第1~3天;每3周1次
    ②顺铂75 mg/m2,静脉滴注,第1天;依托泊苷100 mg/m2,静脉滴注,第1~3天;每3周1次
    ③顺铂60 mg/m2,静脉滴注,第1天;依托泊苷120 mg/m2,静脉滴注,第1~3天;每3周1次
    卡铂+依托泊苷[34] 卡铂AUC=5~6,静脉滴注,第1天;依托泊苷100 mg/m2,静脉滴注,第1~3天;每3周1次
    顺铂+伊立替康[35-36] ①顺铂60 mg/m2,静脉滴注>1 h,第1天;伊立替康60 mg/m2,静脉滴注90 min,第1、8、15天;每4周1次
    ②顺铂30 mg/m2,静脉滴注>1 h,第1、8天;伊立替康65 mg/m2,静脉滴注90 min,第1、8天;每3周1次
    AUC:同表 3
    下载: 导出CSV

    表  7  晚期上皮性卵巢癌含铂化疗方案

    方案 用法
    首选方案
      紫杉醇+卡铂[39-40] 紫杉醇175 mg/m2,静脉滴注>3 h,第1天;卡铂AUC=5~6,静脉滴注>1 h,第1天;间隔3周,共6个疗程a
    其他可选方案
      多西他赛+卡铂[43] 多西他赛60~75 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=5~6,静脉滴注>1 h,第1天;间隔3周,共6个疗程a
      紫杉醇+顺铂[53-54] 紫杉醇135 mg/m2,静脉滴注>24 h,第1天,60 mg/m2,腹腔注射,第8天;顺铂75~100 mg/m2,腹腔注射,第2天;间隔3周,共6个疗程
      PLD+卡铂[44] PLD 30 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=5~6,静脉滴注>1 h,第1天;间隔4周,共3~6个疗程a
      紫杉醇+卡铂[47-50] ①紫杉醇80 mg/m2,静脉滴注>1 h,第1、8、15天;卡铂AUC=5~6,静脉滴注>1 h,第1天;卡铂间隔3周,共6个疗程
    ②紫杉醇60 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=2,静脉滴注>30 min,第1天;每周1次,共18次b
      紫杉醇+卡铂+贝伐珠
    单抗贝伐珠单抗(维
    持)[45-46]
    ①紫杉醇175 mg/m2,静脉滴注>3 h,第1天;卡铂AUC=6,静脉滴注>1 h,第1天;贝伐珠单抗(第2疗程起)15 mg/kg,静脉滴注>1 h,第1天;贝伐珠单抗(维持)15 mg/kg,静脉滴注>1 h;间隔3周,三药联合共5个疗程后贝伐珠单抗单药间隔3周1次,共16次c
    ②紫杉醇175 mg/m2,静脉滴注>3 h,第1天;卡铂AUC=5~6,静脉滴注>1 h,第1天;贝伐珠单抗7.5 mg/kg,静脉滴注>1 h,第1天;贝伐珠单抗(维持)7.5 mg/kg,静脉滴注>1 h;间隔3周,三药联合共5~6个疗程后贝伐珠单抗单药间隔3周1次,共12次c
    AUC:同表 3;PLD:聚乙二醇化脂质体多柔比星;a早期卵巢癌可选方案,Ⅰ期高级别浆液性卵巢癌推荐6个疗程,其他类型为3~6个疗程;b更适合全身状况差的患者;c贝伐珠单抗及其生物类似物
    下载: 导出CSV

    表  8  老年晚期上皮性卵巢癌初始含铂化疗方案

    方案 用法
    紫杉醇+卡铂[58] 紫杉醇135 mg/m2,静脉滴注>3 h,第1天;卡铂AUC=5,静脉滴注>1 h,第1天;间隔3周,共6个疗程a
    紫杉醇+卡铂[50, 57] 紫杉醇60 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=2,静脉滴注>30 min,第1天;每周1次,共18次
    卡铂单药[56, 58-59] 卡铂AUC=5,静脉滴注>1 h,第1天;间隔3周,共6个疗程
    AUC:同表 3a早期卵巢癌可选方案,Ⅰ期高级别浆液性卵巢癌推荐6个疗程,其他类型为3~6个疗程
    下载: 导出CSV

    表  9  铂敏感复发卵巢癌含铂化疗方案

    方案 用法
    首选方案
      紫杉醇+卡铂±贝伐珠单抗[62, 66] 紫杉醇175 mg/m2,静脉滴注>3 h,第1天;卡铂AUC=5,静脉滴注>30 min,第1天;贝伐珠单抗15 mg/kg,静脉滴注>1 h;三药联合,间隔3周,共6~8个疗程,达CR/PR后贝伐珠单抗静脉滴注间隔3周1次,维持至PD或不良反应不耐受
    其他可选方案
      PLD+卡铂±贝伐珠单抗[64, 67] PLD 30 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=5,静脉滴注>30 min,第1天;贝伐珠单抗10 mg/kg,第1、15天;三药联合,间隔4周,共6~10个疗程,达CR/PR后贝伐珠单抗15 mg/kg间隔3周1次,维持至PD或不良反应不耐受
      吉西他滨+卡铂±贝伐珠单抗[63, 65] 吉西他滨1000 mg/m2,静脉滴注>30 min,第1、8天;卡铂AUC=5,静脉滴注>30 min,第1天;贝伐珠单抗15 mg/kg,静脉滴注>1 h;三药联合,间隔3周,共6个疗程,达CR/PR后贝伐珠单抗间隔3周1次,维持至PD或不良反应不耐受
      多西他赛+卡铂[68] 多西他赛75 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=5,静脉滴注>30 min,第1天;间隔3周,共6个疗程
      卡铂单药[63] 卡铂AUC=5,静脉滴注>30 min,第1天;间隔3周,共6个疗程
      顺铂单药[62] 顺铂75 mg/m2,静脉滴注>30 min,第1天;间隔3周,共6个疗程
      紫杉醇+奈达铂[74] 紫杉醇175 mg/m2,静脉滴注>3 h,第1天;奈达铂80 mg/m2,静脉滴注>1 h,第1天;间隔3周,共6个疗程
      洛铂单药[75] 洛铂50 mg/m2,静脉滴注,每4周1次
    AUC:同表 3;CR:完全缓解;PR:部分缓解;PD:疾病进展;PLD:同表 7
    下载: 导出CSV

    表  10  铂耐药复发卵巢癌含铂化疗方案

    方案 用法
    奥沙利铂单药[71-73] 奥沙利铂130 mg/m2,静脉滴注,第1天;间隔3周,共4~6个疗程
    多西他赛+洛铂[76] 多西他赛80 mg/m2,静脉滴注,第1天;洛铂30 mg/m2,静脉滴注,第2天;每3周1次
    下载: 导出CSV

    表  11  Ⅰ期上皮性卵巢癌术后管理推荐

    肿瘤类型 病理分期 推荐处理方案
    观察 标准以铂类药物为基础的化疗(静脉注射方式)* 其他辅助性全身治疗
    高级别浆液性癌 ⅠA/B/C期 - -
    G2子宫内膜样癌 ⅠA/B期 -
    G3子宫内膜样癌 ⅠA/B/C期 - -
    癌肉瘤 ⅠA/B/C期 - 卡铂+异环磷酰胺
    顺铂+异环磷酰胺
    紫杉醇+异环磷酰胺(2B类)
    透明细胞癌 ⅠA期 -
    透明细胞癌 ⅠB/C期 - -
    黏液性癌 ⅠA/B期 - -
    黏液性癌 ⅠC期 5-FU+亚叶酸钙+奥沙利铂
    卡培他滨+奥沙利铂
    G1子宫内膜样癌 ⅠA/B期 - -
    G1子宫内膜样癌 ⅠC期 √(2B类) 激素治疗(2B类)
    低级别浆液性癌 ⅠA/B期 - -
    低级别浆液性癌 ⅠC期 √(2B类) 激素治疗(2B类)
    -:不推荐;√:推荐;*可在Ⅰ期患者应用紫杉醇+卡铂、多西他赛+卡铂、PLD+卡铂;5-FU:5-氟尿嘧啶;PLD:同表 7
    下载: 导出CSV

    表  12  Ⅱ~Ⅳ期上皮性卵巢癌术后管理推荐

    肿瘤类型 推荐处理方案
    标准以铂类药物为基础的化疗±贝伐珠单抗(静脉注射方式) 其他治疗
    高级别浆液性癌 IP/Ⅳ紫杉醇+顺铂(Ⅲ期满意肿瘤细胞减灭术)
    G2/3子宫内膜样癌 IP/Ⅳ紫杉醇+顺铂(Ⅲ期满意肿瘤细胞减灭术)
    癌肉瘤 IP/Ⅳ紫杉醇+顺铂(Ⅲ期满意肿瘤细胞减灭术)
    卡铂+异环磷酰胺
    顺铂+异环磷酰胺
    紫杉醇+异环磷酰胺(2B类)
    透明细胞癌 IP/Ⅳ紫杉醇+顺铂(Ⅲ期满意肿瘤细胞减灭术)
    黏液性癌 5-FU+亚叶酸钙+奥沙利铂±贝伐珠单抗(贝伐珠单抗为2B类)
    卡培他滨+奥沙利铂±贝伐珠单抗(贝伐珠单抗为2B类)
    低级别浆液性癌 内分泌治疗(2B类)
    G1子宫内膜样癌 内分泌治疗(2B类)
    √:推荐;IP:腹腔注射;Ⅳ:静脉注射; 5-FU:同表 11
    下载: 导出CSV

    表  13  上皮性卵巢癌化疗方案

    方案 用法
    顺铂+异环磷酰胺[77] 顺铂40 mg/m2,静脉滴注,第1天;异环磷酰胺1200 mg/m2,静脉滴注,第1~4天;每4周重复
    卡铂+异环磷酰胺[78] 卡铂AUC=5,静脉滴注,第1天;异环磷酰胺3000 mg/m2,静脉滴注,第1天;每3周重复
    伊立替康+顺铂[79] 伊立替康60 mg/m2,静脉滴注,第1、8、15天;顺铂60 mg/m2,静脉滴注,第1天;每4周重复
    FOLFOX-4[80] 奥沙利铂85 mg/m2,静脉滴注>2 h,第1天;四氢叶酸200 mg/m2,静脉滴注>2 h,第1天;5-FU 400 mg/m2,静脉推注,第1天,然后600 mg/m2,持续静脉滴注22 h,第1~2天;每3周重复
    FOLFOX+贝伐珠单抗[81] 奥沙利铂85 mg/m2,静脉滴注>2 h,第1天;四氢叶酸200 mg/m2,静脉滴注>2 h,第1天;5-FU 400 mg/m2,静脉推注,第1天,然后600 mg/m2,持续静脉滴注22 h,第1~2天;贝伐珠单抗5 mg/kg,静脉滴注,第1天;每2周重复
    奥沙利铂+卡培他滨[82] 奥沙利铂130 mg/m2,静脉滴注>2 h,第1天;卡培他滨每次850 mg/m2,2次/d,口服,第1~14天;每3周重复
    奥沙利铂+卡培他滨+贝伐珠单抗[82] 奥沙利铂130 mg/m2,静脉滴注>2 h,第1天;卡培他滨每次850 mg/m2,2次/d,口服,第1~14天;贝伐珠单抗15 mg/kg,静脉滴注,第1天;每3周重复
    AUC:同表 3;5-FU:同表 11
    下载: 导出CSV

    表  14  卵巢生殖细胞肿瘤初始化疗方案

    方案 用法
    博来霉素+依托泊苷+顺铂[90-91] 博来霉素30 U/周,静脉滴注;依托泊苷100 mg/m2,静脉滴注,第1~5天;顺铂20 mg/m2,静脉滴注,第1~5天;每3周重复
    卡铂+依托泊苷[92] 卡铂400 mg/m2,静脉滴注,第1天;依托泊苷120 mg/m2,静脉滴注,第1~3天;每4周重复
    博来霉素+依托泊苷+顺铂
    (儿童)[93]
    博来霉素15 U/m2,第1天;依托泊苷167 mg/m2,静脉滴注,第1~3天;顺铂33 mg/m2,静脉滴注,第1~3天;每3周重复
    注:博来霉素的主要不良反应为肺纤维化、间质性肺炎,用药期间应注意复查胸部X线片和肺功能,一旦出现肺毒性症状应立即停药,终身剂量不超过270 U
    下载: 导出CSV

    表  15  卵巢生殖细胞肿瘤复发后化疗方案

    方案 用法
    紫杉醇+异环磷酰胺+顺铂[94] 紫杉醇250 mg/m2,持续静脉滴注24 h,第1天;异环磷酰胺1500 mg/m2,静脉滴注>60 min,第2~5天;顺铂25 mg/m2,静脉滴注>30 min,第2~5天;每3周重复
    顺铂+依托泊苷[99] 顺铂20 mg/m2,静脉滴注,第1~5天;依托泊苷100 mg/m2,静脉滴注,第1~5天;每3周重复
    依托泊苷+异环磷酰胺+顺铂[95] 依托泊苷75 mg/m2,静脉滴注>60 min,第1~5天;异环磷酰胺1200 mg/m2,静脉滴注,第1~5天;顺铂20 mg/m2,静脉滴注>60 min,第1~5天;每3周重复
    长春碱+异环磷酰胺+顺铂[97] 长春碱0.11 mg/kg,静脉滴注,5~10 min,第1~2天;异环磷酰胺1200 mg/m2,静脉滴注,第1~5天;顺铂20 mg/m2,静脉滴注>60 min,第1~5天;每3周重复
    下载: 导出CSV

    表  16  子宫内膜癌含铂化疗方案

    方案 用法
    卡铂+紫杉醇[112] 卡铂AUC=5,静脉滴注>1 h;紫杉醇175 mg/m2,静脉滴注>3 h;每3周1次
    卡铂+紫杉醇+曲妥珠单抗[116] 紫杉醇175 mg/m2,静脉滴注>3 h;卡铂AUC =5,静脉滴注>1 h;首次曲妥珠单抗8 mg/kg(随后周期6 mg/kg),静脉滴注;每3周1次
    卡铂+多西他赛[119-120] 多西他赛60~75 mg/m2,静脉滴注>1 h,第1天;卡铂AUC=5,静脉滴注>1 h,第1天;每3周1次
    顺铂+多柔比星[110-111] 多柔比星60 mg/m2,静脉滴注>1 h;顺铂50 mg/m2,静脉滴注>1 h;每3周1次
    顺铂+多柔比星+紫杉醇[111] 紫杉醇160 mg/m2,静脉滴注>3 h;多柔比星45 mg/m2,静脉滴注>1 h;顺铂50 mg/m2,静脉滴注>1 h;每3周1次
    卡铂+紫杉醇+贝伐珠单抗[113] 紫杉醇175 mg/m2,静脉滴注>3 h;卡铂AUC=5,静脉滴注>1 h;贝伐珠单抗15 mg/kg,静脉滴注30~90 min;每3周1次
    顺铂单药 顺铂50~75 mg/m2,静脉滴注>1 h,每3周1次,需要水化
    卡铂单药 卡铂AUC = 4~5,静脉滴注>1 h,每3周1次
    奥沙利铂单药[115] 奥沙利铂130 mg/m2,静脉滴注>2 h,每3周1次
    奈达铂+伊立替康[114] 伊立替康40~70 mg/m2,静脉滴注,第1、8、15天;奈达铂50 mg/m2,静脉滴注,第1天;每4周1次
    顺铂+异环磷酰胺[117] 顺铂20 mg/m2,静脉滴注×5 d;异环磷酰胺1500 mg/m2,静脉滴注×5 d;每3周1次
    AUC:同表 3
    下载: 导出CSV

    表  17  妊娠滋养细胞肿瘤含铂化疗方案

    方案 用法
    EMA/EP[127] EMA:依托泊苷100 mg/m2,第1~2天;甲氨蝶呤100 mg/m2静脉滴注→200 mg/m2静脉滴注12 h,第1天;四氢叶酸15 mg,口服或肌内注射,每12小时1次×4次;放线菌素D 0.5 mg,静脉滴注,第1~2天
    EP:依托泊苷100 mg/m2,静脉滴注,第8天;顺铂75 mg/m2,静脉滴注,第8天
    EMA和EP每周交替,2周为1个疗程,第15天开始下1个疗程
    EP/EMA[126] EP:依托泊苷150 mg/m2,静脉滴注,第1天;顺铂75 mg/m2,静脉滴注,第1天
    EMA:依托泊苷100 mg/m2,第8天;甲氨蝶呤300 mg/m2,静脉滴注,第8天;四氢叶酸15 mg,口服或肌内注射,每12小时1次×4次;放线菌素D 0.5 mg,静脉滴注,第8天
    第15天开始下1个疗程
    ICE[130] 依托泊苷100 mg/m2,第1~3天;异环磷酰胺1.2 g/m2,第1~3天;卡铂300 mg/m2,第1天;21天为1个疗程
    TP/TE[129] TP:紫杉醇135 mg/m2+顺铂60 mg/m2
    TE:紫杉醇135 mg/m2+依托泊苷150 mg/m2
    TP和TE两周交替,4周为1个疗程
    VIP[130] 依托泊苷75 mg/m2,第1~4天;异环磷酰胺1.2 g/m2,第1~4天;顺铂20 mg/m2,第1~4天;21天为1个疗程
    BEP[130] 顺铂20 mg/m2,第1~5天;依托泊苷100 mg/m2,第1~5天;博来霉素15 mg/mm2,第1~2天;21天为1个疗程
    EP[125] 依托泊苷100 mg/m2,第1~2天;顺铂20 mg/m2,第1~2天;7天为1个疗程
    下载: 导出CSV

    表  18  药物反应症状

    药物反应 轻度(输注反应) 严重(过敏反应) 致命(过敏反应)
    铂类 非铂类 铂类 非铂类 铂类 非铂类
    潮热 × ×
    皮肤
      皮疹 × ×
      瘙痒 × ×
      全身性荨麻疹 × ×
    胸部、腹部、盆腔或背部疼痛 × × ×
    呼吸系统
      呼吸短促、困难 × ×
      呼吸系统受损 × ×
    心血管系统
      血压改变需处理 × ×
      严重低血压 × ×
    消化系统(如恶心、呕吐) × × × ×
    急性发作 × ×
    濒死感、焦虑、不适 × ×
    停止输注后症状迅速缓解 × ×
    注:×表示出现药物反应
    下载: 导出CSV
  • [1] Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemo-therapy[J]. Radiol Oncol, 2019, 53: 148-158. doi:  10.2478/raon-2019-0018
    [2] Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ⅰ B cervical carcinoma[J]. N Engl J Med, 1999, 340: 1154-1161. doi:  10.1056/NEJM199904153401503
    [3] Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J]. N Engl J Med, 1999, 340: 1137-1143. doi:  10.1056/NEJM199904153401501
    [4] Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J]. J Clin Oncol, 2000, 18: 1606-1613. doi:  10.1200/JCO.2000.18.8.1606
    [5] Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage Ⅱ B-Ⅳ A carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study[J]. J Clin Oncol, 1999, 17: 1339-1348. doi:  10.1200/JCO.1999.17.5.1339
    [6] Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340: 1144-1153. doi:  10.1056/NEJM199904153401502
    [7] Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer[J]. Gynecol Oncol, 2008, 108: 195-200. doi:  10.1016/j.ygyno.2007.09.022
    [8] Higgins RV, Naumann WR, Hall JB, et al. Concurrent carboplatin with pelvic radiation therapy in the primary treat-ment of cervix cancer[J]. Gynecol Oncol, 2003, 89: 499-503. doi:  10.1016/S0090-8258(03)00151-3
    [9] Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage ⅠB2, ⅡA, or ⅡB Squamous Cervical Cancer: A Randomized Controlled Trial[J]. J Clin Oncol, 2018, 36: 1548-1555. doi:  10.1200/JCO.2017.75.9985
    [10] Greggi S, Kenter G, Vergote I, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for StageⅠ B2-Ⅱ B cervical cancer: EORTC55994[J]. Int J Gynecol Cancer, 2019, 29: A12. doi:  10.1136/ijgc-2019-000666
    [11] Sehouli J, Runnebaum IB, Fotopoulou C, et al. A randomized phase Ⅲ adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study[J]. Ann Oncol, 2012, 23: 2259-2264. doi:  10.1093/annonc/mdr628
    [12] Huang H, Feng Y, Wan T, et al. Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage Ⅰ B1-Ⅱ A2 cervical cancer (STARS Study): A randomized, controlled, openlabel, phase Ⅲ trial[C]. American Society of Clinical Oncology, 2020.
    [13] Hosaka M, Watari H, Takeda M, et al. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymph-adenectomy[J]. J Obstet Gynaecol Res, 2008, 34: 552-556. doi:  10.1111/j.1447-0756.2008.00739.x
    [14] Lee KB, Lee JM, Ki KD, et al. Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stageⅠ B-Ⅱ A cervical cancer[J]. Int J Gynecol Cancer, 2008, 18: 1027-1031. doi:  10.1111/j.1525-1438.2007.01136.x
    [15] Takeshima N, Umayahara K, Fujiwara K, et al. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage Ⅰ B-Ⅱ A cervical cancer[J]. Gynecol Oncol, 2006, 103: 618-622. doi:  10.1016/j.ygyno.2006.04.019
    [16] Weng D, Wang H, Zhu C, et al. Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002)[J]. Gynecol Oncol, 2018, 149: 30. doi:  10.1016/j.ygyno.2018.04.070
    [17] Moore DH, Blessing JA, McQuellon RP, et al. Phase Ⅲ study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. J Clin Oncol, 2004, 22: 3113-3119. doi:  10.1200/JCO.2004.04.170
    [18] Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2005, 23: 4626-4633. doi:  10.1200/JCO.2005.10.021
    [19] Monk BJ, Sill MW, McMeekin DS, et al. Phase Ⅲ trial of four cisplatin-containing doublet combinations in stage ⅣB, recurrent, or persistent cervical carcinoma: a Gynecolo-gic Oncology Group study[J]. J Clin Oncol, 2009, 27: 4649-4655. doi:  10.1200/JCO.2009.21.8909
    [20] Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase Ⅲ Trial JCOG0505[J]. J Clin Oncol, 2015, 33: 2129-2135. doi:  10.1200/JCO.2014.58.4391
    [21] Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370: 734-743. doi:  10.1056/NEJMoa1309748
    [22] Takekuma M, Hirashima Y, Ito K, et al. Phase Ⅱ trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study[J]. Gynecol Oncol, 2012, 126: 341-345. doi:  10.1016/j.ygyno.2012.05.010
    [23] Li Y, Zeng J, Huang M, et al. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma[J]. Cancer, 2017, 123: 420-425. doi:  10.1002/cncr.30328
    [24] Kuo DY, Blank SV, Christos PJ, et al. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study[J]. Gynecol Oncol, 2010, 116: 442-446. doi:  10.1016/j.ygyno.2009.10.082
    [25] Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document[J]. Gynecol Oncol, 2011, 122: 190-198. doi:  10.1016/j.ygyno.2011.04.011
    [26] Wang KL, Chang TC, Jung SM, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study[J]. Eur J Cancer, 2012, 48: 1484-1494. doi:  10.1016/j.ejca.2011.12.014
    [27] Kuji S, Hirashima Y, Nakayama H, et al. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan[J]. Gynecol Oncol, 2013, 129: 522-527. doi:  10.1016/j.ygyno.2013.02.025
    [28] Boruta DM 2nd, Schorge JO, Duska LA, et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix[J]. Gynecol Oncol, 2001, 81: 82-87. doi:  10.1006/gyno.2000.6118
    [29] Zivanovic O, Leitao MM Jr, Park KJ, et al. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy[J]. Gynecol Oncol, 2009, 112: 590-593. doi:  10.1016/j.ygyno.2008.11.010
    [30] Tempfer CB, Tischoff I, Dogan A, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature[J]. BMC Cancer, 2018, 18: 530. doi:  10.1186/s12885-018-4447-x
    [31] Nagao S, Miwa M, Maeda N, et al. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review[J]. Int J Gynecol Cancer, 2015, 25: 1300-1305. doi:  10.1097/IGC.0000000000000495
    [32] Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017, 18: 1116-1125. doi:  10.1016/S1470-2045(17)30318-2
    [33] Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340: 265-271. doi:  10.1056/NEJM199901283400403
    [34] Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase Ⅱ study of the Hellenic Cooperative Oncology Group (HeCOG)[J]. Ann Oncol, 2001, 12: 1231-1238. doi:  10.1023/A:1012295131640
    [35] Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002, 346: 85-91. doi:  10.1056/NEJMoa003034
    [36] Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J]. J Clin Oncol, 2006, 24: 2038-2043. doi:  10.1200/JCO.2005.04.8595
    [37] McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer[J]. N Engl J Med, 1996, 334: 1-6. doi:  10.1056/NEJM199601043340101
    [38] Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results[J]. J Natl Cancer Inst, 2000, 92: 699-708. doi:  10.1093/jnci/92.9.699
    [39] Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21: 3194-3200. doi:  10.1200/JCO.2003.02.153
    [40] du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer[J]. J Natl Cancer Inst, 2003, 95: 1320-1329. doi:  10.1093/jnci/djg036
    [41] Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an explora-tory analysis of a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 116: 301-306. doi:  10.1016/j.ygyno.2009.10.073
    [42] Trimbos JB, Vergote I, Bolis G, et al. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial[J]. J Natl Cancer Inst, 2003, 95: 113-125. doi:  10.1093/jnci/95.2.113
    [43] Vasey PA, Jayson GC, Gordon A, et al. Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma[J]. J Natl Cancer Inst, 2004, 96: 1682-1691. doi:  10.1093/jnci/djh323
    [44] Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase Ⅲ trial[J]. J Clin Oncol, 2011, 29: 3628-3635. doi:  10.1200/JCO.2010.33.8566
    [45] Burger RA, Brady MF, Bookman MA, et al. Incorpo-ration of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011, 365: 2473-2483. doi:  10.1056/NEJMoa1104390
    [46] Oza AM, Cook AD, Pfisterer J, et al. Standard chemo-therapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial[J]. Lancet Oncol, 2015, 16: 928-936. doi:  10.1016/S1470-2045(15)00086-8
    [47] Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial[J]. Lancet, 2009, 374: 1331-1338. doi:  10.1016/S0140-6736(09)61157-0
    [48] Chan JK, Brady MF, Penson RT, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer[J]. N Engl J Med, 2016, 374: 738-748. doi:  10.1056/NEJMoa1505067
    [49] Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial[J]. Lancet, 2019, 394: 2084-2095. doi:  10.1016/S0140-6736(19)32259-7
    [50] Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15: 396-405. doi:  10.1016/S1470-2045(14)70049-X
    [51] Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage Ⅲ ovarian cancer[J]. N Engl J Med, 1996, 335: 1950-1955. doi:  10.1056/NEJM199612263352603
    [52] Markman M, Bundy BN, Alberts DS, et al. Phase Ⅲ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage Ⅲ ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2001, 19: 1001-1007. doi:  10.1200/JCO.2001.19.4.1001
    [53] Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354: 34-43. doi:  10.1056/NEJMoa052985
    [54] Walker JL, Brady MF, Wenzel L, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study[J]. J Clin Oncol, 2019, 37: 1380-1390. doi:  10.1200/JCO.18.01568
    [55] van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer[J]. N Engl J Med, 2018, 378: 230-240. doi:  10.1056/NEJMoa1708618
    [56] International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial[J]. Lancet, 2002, 360: 505-515. doi:  10.1016/S0140-6736(02)09738-6
    [57] Pignata S, Breda E, Scambia G, et al. A phase Ⅱ study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study[J]. Crit Rev Oncol Hematol, 2008, 66: 229-236. doi:  10.1016/j.critrevonc.2007.12.005
    [58] von Gruenigen VE, Huang HQ, Beumer JH, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study[J]. Gynecol Oncol, 2017, 144: 459-467. doi:  10.1016/j.ygyno.2016.11.033
    [59] Falandry C, Rousseau F, Mouret-Reynier MA, et al. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial[J]. JAMA Oncol, 2021, 7: 853-861. doi:  10.1001/jamaoncol.2021.0696
    [60] Pignata S, Scambia G, Bologna A, et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study[J]. J Clin Oncol, 2017, 35: 3347-3353. doi:  10.1200/JCO.2017.73.4293
    [61] Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data[J]. Ann Oncol, 2013, 24: 3028-3034. doi:  10.1093/annonc/mdt406
    [62] Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial[J]. Lancet, 2003, 361: 2099-2106.
    [63] Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG[J]. J Clin Oncol, 2006, 24: 4699-4707. doi:  10.1200/JCO.2006.06.0913
    [64] Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse[J]. J Clin Oncol, 2010, 28: 3323-3329. doi:  10.1200/JCO.2009.25.7519
    [65] Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Clin Oncol, 2012, 30: 2039-2045. doi:  10.1200/JCO.2012.42.0505
    [66] Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18: 779-791. doi:  10.1016/S1470-2045(17)30279-6
    [67] Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21: 699-709. doi:  10.1016/S1470-2045(20)30142-X
    [68] Strauss HG, Henze A, Teichmann A, et al. Phase Ⅱ trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer[J]. Gynecol Oncol, 2007, 104: 612-616. doi:  10.1016/j.ygyno.2006.09.023
    [69] Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase Ⅱ trial[J]. Gynecol Oncol, 2007, 105: 358-364. doi:  10.1016/j.ygyno.2006.12.018
    [70] Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma[J]. Int J Gynecol Cancer, 2005, 15: 18-22. doi:  10.1136/ijgc-00009577-200505001-00004
    [71] Dieras V, Bougnoux P, Petit T, et al. Multicentre phase Ⅱ study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients[J]. Ann Oncol, 2002, 13: 258-266. doi:  10.1093/annonc/mdf018
    [72] Chollet P, Bensmaïne MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer[J]. Ann Oncol, 1996, 7: 1065-1070. doi:  10.1093/oxfordjournals.annonc.a010500
    [73] Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase Ⅱ study of the European Organization for Research and Treatment of Cancer Gynecology Group[J]. J Clin Oncol, 2000, 18: 1193-1202. doi:  10.1200/JCO.2000.18.6.1193
    [74] Ge L, Li N, Yuan GW, et al. Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer[J]. Am J Cancer Res, 2018, 8: 1074-1082. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_american-journal-cancer-research_thesis/040004261840.html
    [75] Gietema JA, Veldhuis GJ, Guchelaar HJ, et al. Phase Ⅱ and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer[J]. Br J Cancer, 1995, 71: 1302-1307. doi:  10.1038/bjc.1995.252
    [76] 李瑛花. 洛铂联合多西他赛治疗复发性卵巢癌的疗效[J]. 中南大学学报(医学版), 2014, 39: 1131-1136. doi:  10.11817/j.issn.1672-7347.2014.11.005
    [77] Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary[J]. Int J Gynecol Cancer, 2008, 18: 22-29. doi:  10.1111/j.1525-1438.2007.00948.x
    [78] Dandamudi RK, Aslam S, Walji N, et al. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna[J]. Anticancer Res, 2015, 35: 4841-4847. http://www.researchgate.net/profile/Dr_Ravi_Dandamudi/publication/280910092_Chemotherapy_for_Uterine_Carcinosarcoma_with_Carboplatin_Ifosfamide_and_Mesna/links/570fff9908ae74cb7d9eff2c.pdf
    [79] Sugiyama T, Okamoto A, Enomoto T, et al. Randomized Phase Ⅲ Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial[J]. J Clin Oncol, 2016, 34: 2881-2887. doi:  10.1200/JCO.2016.66.9010
    [80] Lee HJ, Kim HS, Park NH, et al. Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer[J]. Cancer Res Treat, 2013, 45: 40-47. doi:  10.4143/crt.2013.45.1.40
    [81] Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with meta-static colorectal cancer: a multicenter phase Ⅱ study[J]. BMC Cancer, 2007, 7: 91. doi:  10.1186/1471-2407-7-91
    [82] Gore M, Hackshaw A, Brady WE, et al. An international, phase Ⅲ randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor[J]. Gynecol Oncol, 2019, 153: 541-548. doi:  10.1016/j.ygyno.2019.03.256
    [83] Powell MA, Filiaci VL, Hensley ML, et al. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage Ⅰ-Ⅳ, persistent or recurrent carcino-sarcoma of the uterus or ovary: An NRG Oncology trial[J]. J Clin Oncol, 2019, 37: 5500. doi:  10.1200/JCO.2019.37.15_suppl.5500
    [84] Rutledge TL, Gold MA, McMeekin DS, et al. Carcinosar-coma of the ovary-a case series[J]. Gynecol Oncol, 2006, 100: 128-132. doi:  10.1016/j.ygyno.2005.07.119
    [85] Sundar S, Symonds RP, Decatris MP, et al. Phase Ⅱ trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy[J]. Gynecol Oncol, 2004, 94: 502-508. doi:  10.1016/j.ygyno.2004.04.020
    [86] Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase Ⅱ study[J]. Gynecol Oncol, 2004, 95: 165-172. doi:  10.1016/j.ygyno.2004.06.029
    [87] Rosa DD, Awada A, Mano MS, et al. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma[J]. Arch Gynecol Obstet, 2008, 278: 457-462. doi:  10.1007/s00404-008-0592-9
    [88] Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report)[J]. Cancer, 1985, 56: 243-248. doi:  10.1002/1097-0142(19850715)56:2<243::AID-CNCR2820560206>3.0.CO;2-T
    [89] Williams SD, Blessing JA, Moore DH, et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group[J]. Ann Intern Med, 1989, 111: 22-27. doi:  10.7326/0003-4819-111-1-22
    [90] Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin[J]. J Clin Oncol, 1990, 8: 715-720. doi:  10.1200/JCO.1990.8.4.715
    [91] Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group[J]. J Clin Oncol, 1994, 12: 701-706. doi:  10.1200/JCO.1994.12.4.701
    [92] Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group[J]. Gynecol Oncol, 2004, 95: 496-499. doi:  10.1016/j.ygyno.2004.07.044
    [93] Billmire DF, Cullen JW, Rescorla FJ, et al. Surveillance after initial surgery for pediatric and adolescent girls with stageⅠovarian germ cell tumors: report from the Children's Oncology Group[J]. J Clin Oncol, 2014, 32: 465-470. http://www.ncbi.nlm.nih.gov/pubmed/24395845
    [94] Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors[J]. J Clin Oncol, 2005, 23: 6549-6555. doi:  10.1200/JCO.2005.19.638
    [95] Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial[J]. Cancer, 2003, 97: 1869-1875. doi:  10.1002/cncr.11271
    [96] Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors[J]. N Engl J Med, 2007, 357: 340-348. doi:  10.1056/NEJMoa067749
    [97] Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor[J]. J Clin Oncol, 1998, 16: 2500-2504. doi:  10.1200/JCO.1998.16.7.2500
    [98] Nichols CR, Roth BJ, Loehrer PJ, et al. Salvage chemotherapy for recurrent germ cell cancer[J]. Semin Oncol, 1994, 21: 102-108. http://europepmc.org/abstract/MED/7992061
    [99] Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin[J]. J Clin Oncol, 1997, 15: 2553-2558. doi:  10.1200/JCO.1997.15.7.2553
    [100] Schneider DT, Calaminus G, Harms D, et al. Ovarian sex cord-stromal tumors in children and adolescents[J]. J Clin Oncol, 2003, 21: 2357-2363. doi:  10.1200/JCO.2003.05.038
    [101] Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent)[J]. Cochrane Database Syst Rev, 2014, 2014: CD006912. http://www.ncbi.nlm.nih.gov/pubmed/24753008
    [102] Park JY, Jin KL, Kim DY, et al. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary[J]. Gynecol Oncol, 2012, 125: 80-86. doi:  10.1016/j.ygyno.2011.12.442
    [103] Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study[J]. Gynecol Oncol, 1999, 72: 131-137. doi:  10.1006/gyno.1998.5304
    [104] Pautier P, Gutierrez-Bonnaire M, Rey A, et al. Combina-tion of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors[J]. Int J Gynecol Cancer, 2008, 18: 446-452. doi:  10.1111/j.1525-1438.2007.01049.x
    [105] Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors[J]. Gynecol Oncol, 2005, 97: 489-496. doi:  10.1016/j.ygyno.2005.01.011
    [106] Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies[J]. Eur J Cancer, 2010, 46: 2422-2431. doi:  10.1016/j.ejca.2010.06.002
    [107] Randall ME, Filiaci VL, Muss H, et al. Randomized phase Ⅲ trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2006, 24: 36-44. doi:  10.1200/JCO.2004.00.7617
    [108] de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial[J]. Lancet Oncol, 2019, 20: 1273-1285. doi:  10.1016/S1470-2045(19)30395-X
    [109] Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer[J]. N Engl J Med, 2019, 380: 2317-2326. doi:  10.1056/NEJMoa1813181
    [110] Thigpen JT, Brady MF, Homesley HD, et al. Phase Ⅲ trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study[J]. J Clin Oncol, 2004, 22: 3902-3908. doi:  10.1200/JCO.2004.02.088
    [111] Fleming GF, Brunetto VL, Cella D, et al. Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2004, 22: 2159-2166. doi:  10.1200/JCO.2004.07.184
    [112] Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase Ⅲ Trial (NRG Oncology/GOG0209)[J]. J Clin Oncol, 2020, 38: 3841-3850. doi:  10.1200/JCO.20.01076
    [113] Rose PG, Ali S, Moslemi-Kebria M, et al. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma[J]. Int J Gynecol Cancer, 2017, 27: 452-458. doi:  10.1097/IGC.0000000000000891
    [114] Miyamoto M, Takano M, Kuwahara M, et al. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review[J]. Cancer Chemother Pharmacol, 2018, 81: 111-117. doi:  10.1007/s00280-017-3454-y
    [115] Fracasso PM, Blessing JA, Molpus KL, et al. Phase Ⅱ study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2006, 103: 523-526. doi:  10.1016/j.ygyno.2006.03.043
    [116] Fader AN, Roque DM, Siegel E, et al. Randomized Phase Ⅱ Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage Ⅲ-Ⅳ) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis[J]. Clin Cancer Res, 2020, 26: 3928-3935. doi:  10.1158/1078-0432.CCR-20-0953
    [117] Sutton G, Brunetto VL, Kilgore L, et al. A phase Ⅲ trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study[J]. Gynecol Oncol, 2000, 79: 147-153. doi:  10.1006/gyno.2000.6001
    [118] Homesley HD, Filiaci V, Markman M, et al. Phase Ⅲ trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2007, 25: 526-531. doi:  10.1200/JCO.2006.06.4907
    [119] Lan C, Huang X, Cao X, et al. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience[J]. Expert Opin Pharmacother, 2013, 14: 535-542. doi:  10.1517/14656566.2013.778243
    [120] Nomura H, Aoki D, Takahashi F, et al. Randomized phaseⅡ study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)[J]. Ann Oncol, 2011, 22: 636-642. doi:  10.1093/annonc/mdq401
    [121] Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study[J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1007-1013. doi:  10.1016/S0360-3016(00)00762-8
    [122] Moore DH, Ali S, Koh WJ, et al. A phase Ⅱ trial of radia-tion therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study[J]. Gynecol Oncol, 2012, 124: 529-533. doi:  10.1016/j.ygyno.2011.11.003
    [123] Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease[J]. Int J Gynaecol Obstet, 2018, 143: 79-85. doi:  10.1002/ijgo.12615
    [124] Li J, Yue H, Wang X, et al. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 238: 164-169. doi:  10.1016/j.ejogrb.2019.05.023
    [125] Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis[J]. J Clin Oncol, 2013, 31: 280-286. http://hwmaint.jco.ascopubs.org/cgi/reprint/31/2/280.pdf
    [126] Mao Y, Wan X, Lv W, et al. Relapsed or refractory gesta-tional trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen[J]. Int J Gynaecol Obstet, 2007, 98: 44-47. doi:  10.1016/j.ijgo.2007.03.037
    [127] Xiang Y, Sun Z, Wan X, et al. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor[J]. J Reprod Med, 2004, 49: 443-446. http://europepmc.org/abstract/MED/15283051
    [128] Cyriac S, Rajendranath R, Sridevi V, et al. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Obstet, 2011, 115: 37-39. doi:  10.1016/j.ijgo.2011.04.017
    [129] Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)[J]. Ann Oncol, 2008, 19: 1578-1583. doi:  10.1093/annonc/mdn181
    [130] Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia[J]. Cochrane Database Syst Rev, 2012(12): CD008891. http://www.researchgate.net/profile/Theresa_Lawrie/publication/233909071_Chemotherapy_for_Resistant_or_Recurrent_Gestational_Trophoblastic_Neoplasia/links/5b86f8ac299bf1d5a731127d/Chemotherapy-for-Resistant-or-Recurrent-Gestational-Trophoblastic-Neoplasia.pdf
    [131] Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists[J]. Dalton Trans, 2018, 47: 6645-6653. doi:  10.1039/C8DT00838H
    [132] 广东省药学会. 铂类药物临床应用与不良反应管理专家共识[J]. 今日药学, 2019, 29: 577-586. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXU201909003.htm
    [133] Kamimura K, Matsumoto Y, Zhou Q, et al. Myelosuppression by chemotherapy in obese patients with gynecological cancers[J]. Cancer Chemother Pharmacol, 2016, 78: 633-641. doi:  10.1007/s00280-016-3119-2
    [134] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic growth factor (2021.V4)[EB/OL ].[2021-08-25]. https://www.nccn.org/profe-ssionals/physician_gls/pdf/growthfactors.pdf.
    [135] Keng MK, Sekeres MA. Febrile neutropenia in hema-tologic malignancies[J]. Curr Hematol Malig Rep, 2013, 8: 370-378. doi:  10.1007/s11899-013-0171-4
    [136] Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma[J]. Semin Oncol, 1996, 23: 83-89. http://www.ncbi.nlm.nih.gov/pubmed/8783673
    [137] Rodgers GM, Gilreath JA. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy[J]. Acta Haematol, 2019, 142: 13-20. doi:  10.1159/000496967
  • 加载中
图(1) / 表(18)
计量
  • 文章访问数:  1220
  • HTML全文浏览量:  107
  • PDF下载量:  227
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-10-12
  • 录用日期:  2021-10-13
  • 网络出版日期:  2021-10-25
  • 刊出日期:  2021-11-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!